What lessons can be learnt from withdrawal of mibefradil from the market?

Lancet. 1998 Jun 20;351(9119):1829-30. doi: 10.1016/s0140-6736(05)78800-0.
No abstract available

Publication types

  • Review

MeSH terms

  • Advertising
  • Benzimidazoles / adverse effects*
  • Calcium Channel Blockers / adverse effects*
  • Drug Approval*
  • Drug Interactions
  • Europe
  • Humans
  • Mibefradil
  • Product Surveillance, Postmarketing*
  • Tetrahydronaphthalenes / adverse effects*
  • United States

Substances

  • Benzimidazoles
  • Calcium Channel Blockers
  • Tetrahydronaphthalenes
  • Mibefradil